Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain

Phase 2WithdrawnNCT05125978

EMS

Overview

The purpose of this study is to evaluate the efficacy and safety of Canadá association in the treatment of chronic pain

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Pain, Chronic

Interventions

CanadáDRUG

Canadá association 1 tablet twice a day

Canadá placeboOTHER

Placebo of Canadá association 1 tablet twice a day

DipyroneDRUG

Dipyrone 1 tablet twice a day

Dipyrone placebo

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form; * Chronic pain during at least 3 months. Exclusion Criteria: * Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants; * History of alcohol abuse or illicit drug use; * Participation in a clinical trial in the year prior to this study; * Pregnancy or risk of pregnacy and lactating participants; * Known hypersensitivity to any of the formula compounds.

Outcomes

Primary Outcomes

Difference in pain intensity assessed by the VAS scale

Change from baseline in the pain intensity escores assessed in medical visits.

Time frame: 12 weeks

Secondary Outcomes

Adverse events

Incidence and severity of adverse events recorded during the study

Time frame: 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.